Quinapril
- Generic Name
- Quinapril
- Brand Names
- Accupril, Accuretic
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N2O5
- CAS Number
- 85441-61-8
- Unique Ingredient Identifier
- RJ84Y44811
- Background
Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat. It is used to treat hypertension and heart failure. ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.
Quinapril was granted FDA approval on 19 November 1991. A combination tablet with hydrochlorothiazide was also approved on 28 December 1999.
- Indication
Quinapril is indicated for the treatment of hypertension and as an adjunct therapy in the treatment of heart failure. Quinapril in combination with hydrochlorothiazide is indicated for the treatment of hypertension.
- Associated Conditions
- Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Left Ventricular Dysfunction
Diabetic Autonomic Neuropathy and Left Ventricular Function
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- AHEPA University Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT05713396
- Locations
- 🇬🇷
Diabetes Center, 1st Propeudetic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, "AHEPA'' Hospital, Thessaloníki, Greece
Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus
- Conditions
- Diabetic Autonomic Neuropathy
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Registration Number
- NCT03031834
A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 329
- Registration Number
- NCT00930722
- Locations
- 🇮🇳
Pfizer Investigational Site, Kolkata, West Bengal, India
Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension
- Conditions
- DiabetesHypertension
- Interventions
- Drug: accupril, placeboDrug: accupril, alpha lipoic acid
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2011-05-05
- Lead Sponsor
- InVasc Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00795262
- Locations
- 🇺🇸
Atlanta Vascular Research Foundation, Tucker, Georgia, United States
A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00651287
- Locations
Pfizer Investigational Site
Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00649649
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg
- Conditions
- Healthy
- Interventions
- Drug: Accuretic™ Tablets 20 mg/25 mg
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 44
- Registration Number
- NCT00648011
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00649103
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg
- Conditions
- Healthy
- Interventions
- Drug: Accuretic™ Tablets 20 mg/25 mg
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00649441
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients
- Conditions
- Hypertension
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2008-05-06
- Lead Sponsor
- Montreal Heart Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00313547
- Locations
- 🇨🇦
Montreal Heart Institute, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.